Global Immune Checkpoint Inhibitors Market Analysis & Forecast Through 2019-2023 - ResearchAndMarkets.com
The "Global Immune Checkpoint Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The immune checkpoint inhibitors market will register a CAGR of almost 3% by 2023.
The growing number of cancer cases being diagnosed across the globe. Various international and national level campaigns are conducted to increase the awareness about cancer and to help early detection of the disease.
High target affinity and specificity of immune checkpoint inhibitors drugs
Most of the approved therapies for cancer treatment have severe side effects, which lowers the patient compliance towards the treatment. Thus, these drawbacks help the immune checkpoint inhibitors market grow.
High costs associated with the treatment
Treatment cost is one of the major challenges for cancer patients. The high cost is mainly due to hospitalization, laboratory costs, and novel immunotherapies.
With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Merck Sharp & Dohme
1. Executive Summary
2. Scope of the Report
3. Market Landscape
4. Market Sizing
5. Five Forces Analysis
6. Market Segmentation by Type
7. Customer Landscape
8. Geographic Landscape
9. Decision Framework
10. Drivers and Challenges
11. Market Trends
12. Vendor Landscape
13. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/sqm9dn/global_immune?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181211005764/en/